Literature DB >> 26152315

Large maculopapular cutaneous lesions are associated with favorable outcome in childhood-onset mastocytosis.

Tim Wiechers1, Anja Rabenhorst1, Tina Schick2, Liane M Preussner1, Anja Förster1, Peter Valent3, Hans-Peter Horny4, Karl Sotlar4, Karin Hartmann5.   

Abstract

BACKGROUND: Mastocytosis, characterized by pathologic accumulation of mast cells, can manifest itself in adulthood or childhood. Pediatric patients usually have cutaneous mastocytosis (CM) with mast cell infiltrates limited to the skin and spontaneous improvement of skin lesions after several years. However, there are some patients with persistent disease resembling adulthood-onset mastocytosis.
OBJECTIVE: The current classification of CM differentiates between 3 subforms. In clinical practice we noticed that different variants of these subforms might exist, particularly in patients with childhood-onset mastocytosis. Therefore, in the present study, we aimed to investigate whether specific cutaneous lesions in patients with childhood-onset mastocytosis are associated with other disease parameters.
METHODS: We analyzed 144 patients with a disease onset of less than age 17 years using a systematic dermatologic approach.
RESULTS: One hundred twenty-two patients presented with maculopapular cutaneous mastocytosis (MPCM), 12 patients presented with diffuse CM, and 10 patients presented with solitary mastocytoma of the skin. Patients with MPCM showed particularly heterogeneous cutaneous lesions and were therefore grouped into 3 variants presenting either with small lesions (MPCM-small, skin lesions <1 cm in diameter; n = 19), large lesions (MPCM-large, skin lesions ≥ 1 cm in diameter; n = 89), or atypical lesions (MPCM-other, n = 14). Patients with MPCM-large lesions, compared with those with MPCM-small lesions, were characterized by significantly lower tryptase levels, shorter disease duration, and earlier disease onset. In addition, more patients with MPCM-large lesions exhibited spontaneous regression of cutaneous lesions.
CONCLUSION: Our data show that patients with MPCM-large lesions compared with those with MPCM-small lesions have a more favorable disease course and suggest exploring the size of cutaneous lesions as a prognostic parameter in childhood-onset MPCM.
Copyright © 2015 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Childhood-onset mastocytosis; KIT mutation; cutaneous mastocytosis; mast cell; mastocytosis; pediatric mastocytosis; prognosis; skin; tryptase; urticaria pigmentosa

Mesh:

Substances:

Year:  2015        PMID: 26152315     DOI: 10.1016/j.jaci.2015.05.034

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  13 in total

Review 1.  [Mastocytosis : Clinical aspects, diagnostics, therapy].

Authors:  U Lippert
Journal:  Hautarzt       Date:  2017-01       Impact factor: 0.751

Review 2.  Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future.

Authors:  Peter Valent; Cem Akin; Karin Hartmann; Gunnar Nilsson; Andreas Reiter; Olivier Hermine; Karl Sotlar; Wolfgang R Sperr; Luis Escribano; Tracy I George; Hanneke C Kluin-Nelemans; Celalettin Ustun; Massimo Triggiani; Knut Brockow; Jason Gotlib; Alberto Orfao; Lawrence B Schwartz; Sigurd Broesby-Olsen; Carsten Bindslev-Jensen; Petri T Kovanen; Stephen J Galli; K Frank Austen; Daniel A Arber; Hans-Peter Horny; Michel Arock; Dean D Metcalfe
Journal:  Cancer Res       Date:  2017-03-02       Impact factor: 12.701

Review 3.  Mastocytosis in Children.

Authors:  Nicholas Klaiber; Santhosh Kumar; Anne-Marie Irani
Journal:  Curr Allergy Asthma Rep       Date:  2017-10-07       Impact factor: 4.806

Review 4.  Pediatric Mastocytosis: Recognition and Management.

Authors:  Julie V Schaffer
Journal:  Am J Clin Dermatol       Date:  2021-03       Impact factor: 7.403

5.  Proceedings from the Inaugural American Initiative in Mast Cell Diseases (AIM) Investigator Conference.

Authors:  Jason Gotlib; Tracy I George; Melody C Carter; K Frank Austen; Bruce Bochner; Daniel F Dwyer; Jonathan J Lyons; Matthew J Hamilton; Joseph Butterfield; Patrizia Bonadonna; Catherine Weiler; Stephen J Galli; Lawrence B Schwartz; Hanneke Oude Elberink; Anne Maitland; Theoharis Theoharides; Celalettin Ustun; Hans-Peter Horny; Alberto Orfao; Michael Deininger; Deepti Radia; Mohamad Jawhar; Hanneke Kluin-Nelemans; Dean D Metcalfe; Michel Arock; Wolfgang R Sperr; Peter Valent; Mariana Castells; Cem Akin
Journal:  J Allergy Clin Immunol       Date:  2021-03-11       Impact factor: 14.290

Review 6.  Childhood Solitary Cutaneous Mastocytoma: Clinical Manifestations, Diagnosis, Evaluation, and Management.

Authors:  Alexander K C Leung; Joseph M Lam; Kin Fon Leong
Journal:  Curr Pediatr Rev       Date:  2019

7.  Case Report: Mastocytosis: The Long Road to Diagnosis.

Authors:  Tiago Azenha Rama; Diana Martins; Nuno Gomes; Jorge Pinheiro; Ana Nogueira; Luís Delgado; José Luís Plácido; Alice Coimbra
Journal:  Front Immunol       Date:  2021-02-12       Impact factor: 7.561

Review 8.  Systemic Mastocytosis: Molecular Landscape and Implications for Treatment.

Authors:  Cecilia Monaldi; Sara De Santis; Manuela Mancini; Samantha Bruno; Michele Cavo; Simona Soverini
Journal:  Mediterr J Hematol Infect Dis       Date:  2021-07-01       Impact factor: 2.576

Review 9.  Recent advances in the understanding and therapeutic management of mastocytosis.

Authors:  Julien Rossignol; Laura Polivka; Leila Maouche-Chrétien; Laurent Frenzel; Patrice Dubreuil; Olivier Hermine
Journal:  F1000Res       Date:  2019-11-22

Review 10.  Molecular Background, Clinical Features and Management of Pediatric Mastocytosis: Status 2021.

Authors:  Magdalena Lange; Karin Hartmann; Melody C Carter; Frank Siebenhaar; Ivan Alvarez-Twose; Inés Torrado; Knut Brockow; Joanna Renke; Ninela Irga-Jaworska; Katarzyna Plata-Nazar; Hanna Ługowska-Umer; Justyna Czarny; Anna Belloni Fortina; Francesca Caroppo; Roman J Nowicki; Bogusław Nedoszytko; Marek Niedoszytko; Peter Valent
Journal:  Int J Mol Sci       Date:  2021-03-04       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.